ImmunityBio (IBRX) Total Liabilities (2013 - 2026)

ImmunityBio (IBRX) has 14 years of Total Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• Total Liabilities for Q1 2026 came in at $1.5 billion, up 69.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 69.5% YoY), and the FY2025 annual result was $1.0 billion, up 14.97% from the prior year.
• Total Liabilities improved to $1.5 billion in Q1 2026 per IBRX's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $1.5 billion in Q1 2026 and troughed at $727.1 million in Q1 2022.
• A 5-year average of $967.3 million and a median of $936.4 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 93.4% in 2022, then retreated 20.11% in 2024.
• A 5-year view of Total Liabilities shows it stood at $812.2 million in 2022, then surged by 34.26% to $1.1 billion in 2023, then fell by 20.11% to $871.1 million in 2024, then climbed by 14.97% to $1.0 billion in 2025, then surged by 51.35% to $1.5 billion in 2026.
• Business Quant data shows IBRX's Total Liabilities at $1.5 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.